Ir al contenido principal

El NICE dará en breve el OK a Luxturna

He visto en Fiercepharma que dice: Amid Zolgensma crisis, Novartis gets a gene therapy boost as NICE embraces Luxturna.
En la web de NICE: NICE recommends novel gene therapy treatment for rare inherited eye disorder  y dice entre otras cosas:
"The list price of voretigene neparvovec is £613,410 per patient. This technology breached the Budget Impact Test, meaning it would have cost the NHS more than £20 million in one of the first three years after being introduced. However, the company has a commercial arrangement with NHS England making the treatment available to the NHS at a discount, the size of which is commercial in confidence."

Por lo que no se publicita el precio

The draft guidance is now with consultees, including the company, healthcare professionals and patient/carer organisations who have the opportunity to appeal against the draft recommendations. If no appeals are received NICE expects to publish final guidance next month.